Phase II Study of Erlotinib and Docetaxel with Concurrent Intensity Modulated Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

BACKGROUND: To establish the efficacy and toxicities of concurrent erlotinib and docetaxel with IMRT for locally advanced head and neck squamous cell carcinoma (HNSCC). METHODS: Patients received daily erlotinib for two weeks, followed by daily IMRT with concurrent weekly docetaxel and daily erlotin...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Head Neck
Main Authors: Yao, Min, Lavertu, Pierre, Savvides, Panayiotis, Woods, Charles, Fu, Pingfu, Gibson, Michael, Rezaee, Rod, Zender, Chad, Wasman, Jay, Sharma, Neelesh, Machtay, Mitchell
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4844765/
https://ncbi.nlm.nih.gov/pubmed/26918562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.24313
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares